IP Library › Granted Patent US 12,358,966
Granted Patent B2
US 12,358,966 · App. 18/333,904 · Granted Jul 15, 2025

Inducible caspases and methods for use

Inventors: Eric M. Ostertag (San Diego, CA); Devon Shedlock (San Diego, CA)
Assignee: Poseida Therapeutics, Inc.
C07K14/705A61K35/17A61K39/0011A61P3/00A61P17/02A61P29/00A61P31/00A61P35/00A61P37/00C07K14/47C07K14/4747C12N5/0636C12N9/50C12N15/52A61K2039/5156A61K2039/5158C12Y304/22036
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,966
App. No.
18/333,904
Granted
Jul 15, 2025
Kind
B2
Abstract

The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

Claims (7)

1. A method of modifying a cell therapy in a subject in need thereof, comprising administering to the subject (a) a population of T cells comprising an inducible caspase polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 10, and (b) an induction agent.

2. The method of claim 1 , wherein the modifying is a termination of the cell therapy or is a depletion of a portion of the population of T cells.

3. The method of claim 1 , further comprising administering an inhibitor of the induction agent to inhibit modification of the cell therapy, thereby restoring the function and/or efficacy of the cell therapy.

4. The method of claim 1 , wherein the cell therapy is an adoptive cell therapy or an ex vivo gene therapy.

5. The method of claim 4 , wherein the population of T cells is autologous.

6. The method of claim 4 , wherein the population of T cells is allogeneic.

7. The method of claim 1 , wherein the induction agent is rimiducid or AP20187.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: OSTERTAG, ERIC M.; SHEDLOCK, DEVON
To: POSEIDA THERAPEUTICS, INC.
Reel/Frame 063946/0857 →
Continuity (4)
Division 17830773 · Jun 2, 2022
Division 16339710
Provisional Application 62405184 · Oct 6, 2016
Related Publication 20230348553A1 · Nov 2, 2023
References Cited (79)
US 4656134A · Ringold · 1987 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4766067A · Biswas · 1988 [cited by applicant]
US 4795699A · Tabor et al. · 1989 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4889818A · Gelfand et al. · 1989 [cited by applicant]
US 4921794A · Tabor et al. · 1990 [cited by applicant]
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 4994370A · Silver et al. · 1991 [cited by applicant]
US 5066584A · Gyllensten et al. · 1991 [cited by applicant]
US 5091310A · Innis · 1992 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5130238A · Malek et al. · 1992 [cited by applicant]
US 5142033A · Innis · 1992 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5266491A · Nagata et al. · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5580734A · Treco et al. · 1996 [cited by applicant]
US 5641670A · Treco et al. · 1997 [cited by applicant]
US 5733761A · Treco et al. · 1998 [cited by applicant]
US 5770359A · Wilson et al. · 1998 [cited by applicant]
US 5827739A · Wilson et al. · 1998 [cited by applicant]
US 6835394B1 · Discher et al. · 2004 [cited by applicant]
US 7217427B2 · Discher et al. · 2007 [cited by applicant]
US 7867512B2 · Discher et al. · 2011 [cited by applicant]
US 9393292B2 · Brenner · 2016 [cited by applicant]
US 9913882B2 · Slawin et al. · 2018 [cited by applicant]
US 11377480B2 · Ostertag et al. · 2022 [cited by applicant]
US 20230002469A1 · Ostertag et al. · 2023 [cited by applicant]
WO WO03020759A2 · 2003 [cited by applicant]
WO WO2006133398A2 · 2006 [cited by applicant]
WO WO2011133635A2 · 2011 [cited by applicant]
WO WO2011146862A1 · 2011 [cited by applicant]
WO WO2012094679A2 · 2012 [cited by applicant]
WO WO2015134877A1 · 2015 [cited by applicant]
WO WO2016022805A1 · 2016 [cited by applicant]
WO WO2016090111A1 · 2016 [cited by applicant]
WO WO2016135470A1 · 2016 [cited by applicant]
WO WO2017004498A1 · 2017 [cited by applicant]
WO WO2017004509A1 · 2017 [cited by applicant]
WO WO2017190091A1 · 2017 [cited by applicant]
US 5,733,746 A, 03/1998, Treco et al. (withdrawn) [cited by applicant]
Khan et al., “AAV6 Vexosomes mediate robust suicide gene delivery in a murine model of hepatocellular carcinoma”, Molecular Therapy Methods & Clinical Development vol. 17, pp. 497-504 Jun. 2020. [cited by examiner]
Warda et al., “Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety swi… [cited by examiner]
Arcone, R. et al. (1988) “Identification of sequences responsible for acute-phase induction of human C-reactive protein” Nucl Acids Res, 16:3195-3207. [cited by applicant]
Bojak, A. et al. (2002) “Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis” Vaccine, 20:1975-1979. [cited by applicant]
Cao et al. “Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.” Cancer Research 69(23): 8987-8995 (2009). [cited by applicant]
Cazeaux, N. et al. (2002) “Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter” Vaccine, 2… [cited by applicant]
Clarkson, T. et al. (Sep. 1998) “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity” Proc Natl Acad Sci, 95(18):10437-10442. [cited by applicant]
Cunningham, B.C. and Wells, J.A. (Jun. 2, 1989) “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis” Science, 244(4908):1081-1085. [cited by applicant]
De Vos, A.M. et al. (1992) “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex” Science, 255:306-312. [cited by applicant]
Di Stasi et al., “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy”. N Engl J Med. Nov. 3, 2011; 365(18): 1673-1683. [cited by applicant]
Donnelly, J.J. et al. (1997) “DNA Vaccines” Annu Rev Immunol, 15:617-648. [cited by applicant]
GenBank Accession No. AH002818 “ [cited by applicant]
Gossen and Bujard, “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters”. Proc Natl Acad Sci U S A, Jun. 15, 1992; 89(12): 5547-5551. [cited by applicant]
Gossen, M. et al. (Jun. 23, 1995) “Transcriptional activation by tetracyclkines in mammalian cells” Science, 268(5218):1766-1769. [cited by applicant]
Iuliucci, J.D. et al. (2001) “Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers” J Clin Pharmacol, 41:870-879. [cited by applicant]
Jin, Z. et al. (2011) “The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor” Gene Therapy, 18:849-856. [cited by applicant]
Kageyama, R. et al. (Feb. 15, 1987) “Differing Utilization of Homologous Transcription Initiation Sites of Rat K and T Kininogen Genes Under Inflammation Condition” J Biol Chem, 262(5):2345-2351. [cited by applicant]
Kemper, K. et al. (2012) “Targeting colorectal cancer stem cells with inducible caspase-9” Apoptosis, 17:528-537. [cited by applicant]
Maus, M.V. et al. (2014) “Antibody-modified T cells: CARs take the front seat for hematologic malignancies” Blood, 123(17):2625-2635. [cited by applicant]
Nakazawa, Y. et al. “Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes” J Immunotherapy, (Jan. 2013); 36(1):3-10. [cited by applicant]
Oliviero, S. et al. (1987) “The human haptoglobin gene: transcriptional regulation during development and acute phase induction” The EMBO Journal, 6(7):1905-1912. [cited by applicant]
Philip, B. et al. (2014) “A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy” Blood, 124(8):1277-1287. [cited by applicant]
Poli, V. et al. (Nov. 1989) “Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes” Proc Natl Acad Sci USA, 86:8202-8206. [cited by applicant]
Prowse, K.R. and H. Baumann (Jan. 1988) “Hepatocyte-Stimulating Factor, β2 Interferon, and Interleukin-1 Enhance Expression of the Rat α1-Acid Glycoprotein Gene via a Distal Upstream Regulatory Region” Mol Cell Biol, 8(… [cited by applicant]
Quntarelli, C. et al. (Oct. 15, 2007) “Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes” Blood, 110(8):2793-2802 [online]. Retrieved from the Inter… [cited by applicant]
Ramos, C.A. et al. (2010) “An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies” Stem Cells, 28:1107-1115. [cited by applicant]
Ron, D. et al. (May 1991) “Angiotensinogen Gene-Inducible Enhancer-Binding Protein 1, a Member of a New Family of Large Nuclear Proteins That Recognize Nuclear Factor kappaB-Binding Sites through a Zinc Finger Motif” Mo… [cited by applicant]
Shan, D. et al. (1999) “Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths” J Immunol, 162:6589-6595. [cited by applicant]
Smith, L.J. et al. (1992) “Human Interleukin 4. The Solution Structure of a Four-helix Bundle Protein” J Mol Biol, 244:899-904. [cited by applicant]
Sprague, J. et al. (Feb. 1983) “Expression of a Recombinant DNA Gene Coding for the Vesicular Stomatitis Virus Nucleocapsid Protein” J Virol, 45(2):773-781. [cited by applicant]
Straathof, K.C. et al. (2005) “An inducible caspase 9 safety switch for T-cell therapy” Blood, 105:4247-4254. [cited by applicant]
Tey, S-K. et al. (2007) “Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation” Biol Blood Marrow Transpl, 13:913-924. [cited by applicant]
Wilson, D.R. et al. (Dec. 1990) “A 58-Base-Pair Region of the Human C3 Gene Confers Synergistic Inducibility by Interleukin-1 and Interleukin-6” Mol Cell Biol, 10(12):6181-6191. [cited by applicant]
Xie, X. et al. (Sep. 2001) “Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer” Cancer Research, 61:6795-6804. [cited by applicant]
Zechner, R. et al. (Jun. 1988) “Recombinant Human Cachectin/Tumor Necrosis Factor but Not Interleukin-1α Downregulates Lipoprotein Lipase Gene Expression at the Transcriptional Level in Mouse 3T3-L1 Adipocytes” Mol Cell… [cited by applicant]
Zhao, H.L. et al. (Sep. 2008) “Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering” Protein Expr Purif, 61(1):73-77. [cited by applicant]
Cited By (1)
US 12,642,876